AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX. The U.S. therapeutic neurotoxin market exceeds $3.5 billion annually and is projected to exceed $5.0 billion by 2030, and thus represents a major opportunity for biosimilar entry. The Company’s lead asset is ABP-450. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.
Innovating the $3.0B therapeutic neurotoxin market.
Same 900 kDa neurotoxin complex approved for cosmetic indications
Differentiated economics to payors and physicians
Managements team with significant neurotoxin and biopharma experience
Learn More